10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
3 citations
,
November 1998 in “PubMed” 9 citations
,
November 1997 in “British Journal of Dermatology”
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
3 citations
,
November 2017 in “International Journal of Pharmacy and Pharmaceutical Sciences” 1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
August 2024 in “Journal of Clinical Medicine” Systemic treatments like hydroxychloroquine and cyclosporine A help with Lichen Planopilaris and Frontal Fibrosing Alopecia, but ongoing treatment is needed.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
339 citations
,
February 2014 in “Journal of The American Academy of Dermatology” Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
12 citations
,
January 1993 in “PubMed” 7 citations
,
September 2024 in “PLANT PHYSIOLOGY” RALF22 is essential for root hair growth in response to fungal emissions in Arabidopsis.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
17 citations
,
October 2017 in “Journal of Cutaneous Medicine and Surgery” No treatment has been proven to effectively stop hair loss or regrow hair in Frontal Fibrosing Alopecia, and more research is needed.
37 citations
,
September 2017 in “Reumatología Clínica” Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.
4 citations
,
March 2017 in “Al-Mi’galaẗ al-sa'udiyaẗ lī-ulum al-ḥayaẗ” Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
123 citations
,
August 2005 in “Journal of the European Academy of Dermatology and Venereology” The study found that Frontal Fibrosing Alopecia affects a broader age range of women and early treatment can help stop hair loss.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
Finasteride, a medication, is being re-evaluated for its effects and uses.